An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy-Reference-Cited by-同舟云学术

An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy

Published:2020-02-01 Issue:3 Volume:59 Page:395-399
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Yoshizawa Tsuyoshi¹,Yamaguchi Kenya¹,Kawata Nozomu²,Ryuzaki Hitomi³,Ogawa Masahiro³,Obinata Daisuke¹,Mochida Junichi¹,Takahashi Satoru¹

Affiliation:

1. Department of Urology, Nihon University School of Medicine, Japan

2. Department of Urology, Nihon University Hospital, Japan

3. Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/3/59_3302-19/_pdf

Reference13 articles.

1. 1. Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 32: 3705-3715, 2014.

2. 2. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138-148, 2013.

3. 3. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14: 1193-1199, 2013.

4. 4. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16: 152-160, 2015.

5. 5. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71: 630-642, 2017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Macrophage Efferocytosis in the Pathogenesis of Apical Periodontitis;International Journal of Molecular Sciences;2024-03-29